Progenitor Cell Therapy Hosts UK Trade Mission; UK Department of Trade and Industry Visits Progenitor Cell Therapy in Tour of Leading U.S. Cell and Tissue Therapy Companies.

MOUNTAIN VIEW, Calif. -- At the request of the United Kingdom Department of Trade and Industry (DTI), Progenitor Cell Therapy was pleased to host a trade delegation last week at its West Coast facility in Mountain View, California.

The aim of the week-long trade mission, entitled "Advanced Cell & Tissue Therapies," was to gain a better understanding of issues related to successful commercialization of cell and tissue therapies from leading U.S. firms. Of particular interest to mission delegates was an opportunity to identify collaborative ventures between U.S. and UK firms.

DTI Mission Leader, Dr. Chris Mason, stated, "The DTI's purpose with this mission was to explore commercialization of cell and tissue therapies. We intend to learn, to facilitate networking between U.S. and UK professionals, and to identify potential partnerships. Progenitor Cell Therapy is a long-standing leader in the field and one that we identified as a source of insight into the costs, technologies, and issues involved in the technical, commercial, and regulatory aspects of commercializing cell and tissue therapies."

"The selection of Progenitor Cell Therapy by the UK Department of Trade and Industry as one of its stops in the tour follows a key-note presentation from Dr. Stewart Craig, PCT's Vice-President and Chief Technology Officer, at a stem cell commercialization conference held in June in Newcastle and hosted by the Centre of Excellence for Life Sciences (CELS)," stated CELS Project Director Philip Aldridge.

"A rapidly growing part of our business," said PCT President and Chief Scientific Officer, Dr. Robert Preti, "is providing consulting, development, and manufacturing services to companies outside the U.S. Hosting the UK DTI mission fit perfectly with our strategy to continue to expand our services to companies in the UK and identify opportunities to expand our manufacturing capacity in Europe."

About Progenitor Cell Therapy, LLC 

Progenitor Cell Therapy (PCT) is a client-based cell therapy services company that supports the development and commercialization of cellular therapies. PCT provides cGMP-compliant cell manufacturing and consulting services that address regulatory, financial, technical, process, and quality system strategies. Services include a full spectrum of support and consulting related to process and product development, validation, due diligence evaluations, tissue collection, processing, and storage, product manufacturing, distribution and transportation. For more information, please visit www.progenitorcelltherapy.com.